DURHAM — Drug company Dova Pharmaceuticals Inc. signed a deal to expand its Durham office space shortly after receiving its first U.S. Food and Drug Administration approval for one of its drugs, according to a Securities and Exchange Commission filing.
Durham-based Dova signed an agreement last week to lease 21,745 square feet of space for its corporate headquarters at 240 Leigh Farm Road.
The company is essentially renewing its lease of its 14,378 square feet of space in the building that it currently subleases from Paidian Research Inc. and leasing an additional 1,961 square feet of office space in Suite 200.
That new space will become available to the company by Aug. 1.
It has also signed an agreement to lease an additional 5,400 square feet — Suite 215 — in the same building by Aug. 1, 2019.
The lease is until Sept. 30, 2023, and the rent will increase by 2.7 percent each year. Dova Pharmaceuticals has an option to renew the lease for an additional five years.
The FDA approved on Monday the company’s drug to treat low blood platelet count in chronic liver disease patients scheduled to undergo a medical procedure. The drug was submitted in November 2017.
Dova Pharmaceuticals went public in June 2017, raising $75 million. Its stock closed Friday at $24.86, down 14 cents.
This story is from the North Carolina Business News Wire, a service of the UNC-Chapel Hill School of Media and Journalism
